Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Biliary01: Rilvegostomig plus chemotherapy as adjuvant therapy after resection of biliary tract cancer
2023-506054-20-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in biliary adenocarcinoma, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 1 more comparing Rilvegostomig + adjuvant chemotherapy with Placebo + adjuvant chemotherapy (2 arms). Primary endpoint: Recurrence-free survival. Planned start May 2024; status: authorised.
02
Drugs
rilvegostomig
03
Conditions
biliary adenocarcinomaintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on 2023-506054-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506054-20-00.